Approval of gene-editing technology for use in the U.S. food supply chain is a major step forward for Genus PIC, which now looks toward U.S. commercialization.

After years of extensive research and a lengthy regulatory approval process, Genus has received clearance from the U.S. Food and Drug Administration for the gene edited PRRS-resistant pig (PRP) to be used in the U.S. food supply chain, in line with expectations. Genus executives note this is a significant step toward commercialization in the U.S.; however, approvals are still needed in key U.S. export markets, such as Mexico, Canada and Japan.

“FDA approval is a fantastic achievement for Genus PIC and represents a major step towards U.S. commercialization. We will now continue to pursue regulatory approvals in other international jurisdictions with a focus on key U.S. export markets” said Jorgen Kokke, Genus chief executive officer.